<DOC>
	<DOCNO>NCT03091127</DOCNO>
	<brief_summary>With recent addition carfilzomib treatment option multiple myeloma , data available yet drug use outside clinical trial setting . This study therefore provide essential data demonstrate real world utilization carfilzomib routine clinical practice , include dosage , administration schedule , regimen , duration treatment reason discontinuation Europe .</brief_summary>
	<brief_title>Real-world Use Carfilzomib Among Patients With Relapsed MM Europe</brief_title>
	<detailed_description>With recent addition carfilzomib treatment option multiple myeloma , data available yet drug use outside clinical trial setting . The Primary Objective describe carfilzomib utilisation routine clinical practice , include dosage , administration schedule , regimen , duration treatment reason discontinuation . âˆ’ Secondary Objectives : - Describe population treat carfilzomib term demographic , multiple myeloma ( MM ) disease characteristic , treatment history , comorbidities . - Describe safety profile carfilzomib routine clinical practice . - Describe response treatment assess physician record medical file . - Describe healthcare resource utilisation subject treat carfilzomib , term unplanned hospitalisation . - Describe reason choose carfilzomib treatment , dose , regimen MM treatment choice . - Describe specific concomitant therapy ( bisphosphonates , thromboprophylaxis , antihypertensive treatment , anti-infective treatment ) whether therapy use prophylaxis treatment . - Describe performance cardiovascular assessment carfilzomib initiation available per routine care ( electrocardiogram [ ECG ] , echocardiography , leave ventricular ejection fraction ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Age 18 year old time carfilzomib initiation Experienced relapse ( regardless type relapse ; molecular , hematologic , and/or symptomatic ) At least one prior line MM treatment receive Carfilzomib treatment initiate per routine practice currently ongoing At least one administration carfilzomib combination regimen ( ie , monotherapy ) receive Provided write informed consent prior abstraction data Subjects previously receive treatment carfilzomib , either participation clinical trial , routine practice , eligible take part study . Subjects enrol carfilzomib clinical trial eligible additionally take part observational study . If subject enrol observational study , also enroll clinical trial MM treatment and/or disease management protocolspecified , subject become ineligible subject 's data censor time subject enrol clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>